(Alliance News) - Genedrive PLC on Monday said the UK's National Institute for Health & Clinical Excellence has begun an evaluation of CYP2C19 genotype testing for Clopidogrel treatment.
The Manchester-based molecular diagnostics company said that its CYP2C19 ID Kit, which is currently in development, has been included in the new NICE Diagnostics Assessment Programme.
Clopidogrel is a drug that is given to ischemic stroke patients to prevent further clot formation. The CYP2C19 test is a rapid point of care test, which provides guidance on which patients will respond to Clopidogrel.
"The CYP2C19 gene is involved in a metabolic pathway in the liver that converts Clopidogrel to its active form. Clopidogrel is less effective in individuals with certain genetic CYP2C19 variants because they do not metabolize Clopidogrel fully," Genedrive explained.
The company also said that its Point of Care genetic screening tests are now included in new NICE reviews, following the MT-RNR1 DAP announcement in June.
Chief Executive Officer David Budd said: "The review is very timely for us, given the current development of our new CYP2C19 ID Point of Care test. The clinical landscape for genotype-guided antiplatelet therapy has advanced in the last two years, with a growing number of pharmacogenetic clinical bodies recommending genotype-guided Clopidogrel administration."
Shares in Genedrive were down 1.6% to 17.95 pence each in London on Monday midday.
By Sophie Rose; sophierose@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Genedrive (GDR)